Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY

EMPA-KIDNEY assessed the effects of empagliflozin 10 mg once daily vs. placebo in 6609 patients with chronic kidney disease (CKD) at risk of progression, including 612 participants from Japan.

Saved in:

Bibliographic Details
Main Authors:	Nangaku, Masaomi (Author) , Herrington, William G. (Author) , Goto, Shinya (Author) , Maruyama, Shoichi (Author) , Kashihara, Naoki (Author) , Ueki, Kohjiro (Author) , Wada, Jun (Author) , Watada, Hirotaka (Author) , Nakashima, Eitaro (Author) , Lee, Ryonfa (Author) , Massey, Dan (Author) , Mayne, Kaitlin J. (Author) , Tomita, Aiko (Author) , Haynes, Richard (Author) , Hauske, Sibylle J. (Author) , Kadowaki, Takashi (Author)
Format:	Article (Journal)
Language:	English
Published:	2024
In:	Clinical and experimental nephrology Year: 2024, Volume: 28, Issue: 6, Pages: 588-595
ISSN:	1437-7799
DOI:	10.1007/s10157-024-02489-4
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s10157-024-02489-4
Author Notes:	Masaomi Nangaku, William G. Herrington, Shinya Goto, Shoichi Maruyama, Naoki Kashihara, Kohjiro Ueki, Jun Wada, Hirotaka Watada, Eitaro Nakashima, Ryonfa Lee, Dan Massey, Kaitlin J. Mayne, Aiko Tomita, Richard Haynes, Sibylle J. Hauske, Takashi Kadowaki

Description
Summary:	EMPA-KIDNEY assessed the effects of empagliflozin 10 mg once daily vs. placebo in 6609 patients with chronic kidney disease (CKD) at risk of progression, including 612 participants from Japan.
Item Description:	Online veröffentlicht: 20. April 2024 Gesehen am 30.10.2024
Physical Description:	Online Resource
ISSN:	1437-7799
DOI:	10.1007/s10157-024-02489-4